Single-pass albumin dialysis as treatment of acute on chronic liver failure during COVID-19 pneumonia. report of one case
No hay miniatura disponible
Archivos
Fecha
2022-11
Profesor/a Guía
Facultad/escuela
Idioma
es
Título de la revista
ISSN de la revista
Título del volumen
Editor
Sociedad Medica de Santiago
Nombre de Curso
Licencia CC
CC BY 4.0 DEED
Attribution 4.0 International
Licencia CC
https://creativecommons.org/licenses/by/4.0/deed.en
Resumen
Liver transplantation is the only effective therapy to reduce the high mortality associated with acute liver failure and acute on chronic liver failure (ACLF). Single-pass albumin dialysis (SPAD) is an extracorporeal supportive therapy used as a bridge to liver transplantation or regeneration. We report a 44-year-old man with alcoholic cirrhosis admitted for critical COVID-19 pneumonia that evolves with ACLF. SPAD technique was performed completing six sessions, with a reduction of bilirubin and ammonia levels. He evolved with severe respiratory failure and refractory septic shock, dying. SPAD is a safe and efficient technique aimed to eliminate liver toxins, preventing multiorgan damage interrupting the process known as the "autointoxication hypothesis". It is easy to implement in any critical patient unit and has lower costs than other extracorporeal liver support therapies. © 2022 Sociedad Medica de Santiago. All rights reserved.
Notas
Indexación: Scopus.
Palabras clave
Acute, Acute-On-Chronic Liver Failure, Artificial, Covid-19, Liver, Liver Failure, Adult, Albumins, Humans, Liver Transplantation, Male, Renal Dialysis
Citación
Revista Medica de Chile, Volume 150, Issue 11, Pages 1540 - 1544, November 2022
DOI
10.4067/S0034-98872022001101540